Rondini Elizabeth A, Pant Asmita, Kocarek Thomas A
Institute of Environmental Health Sciences, Wayne State University, Detroit, Michigan.
Institute of Environmental Health Sciences, Wayne State University, Detroit, Michigan
J Pharmacol Exp Ther. 2015 Dec;355(3):429-41. doi: 10.1124/jpet.115.226365. Epub 2015 Oct 1.
Cytosolic sulfotransferase 1C2 (SULT1C2) is expressed in the kidney, stomach, and liver of rats; however, the mechanisms regulating expression of this enzyme are not known. We evaluated transcriptional regulation of SULT1C2 by mevalonate (MVA)-derived intermediates in primary cultured rat hepatocytes using several cholesterol synthesis inhibitors. Blocking production of mevalonate with the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin (30 μM), reduced SULT1C2 mRNA content by ∼40% whereas the squalene synthase inhibitor squalestatin (SQ1, 0.1 μM), which causes accumulation of nonsterol isoprenoids, increased mRNA content by 4-fold. Treatment with MVA (10 mM) strongly induced SULT1C2 mRNA by 12-fold, and this effect was blocked by inhibiting squalene epoxidase but not by more distal cholesterol inhibitors, indicating the effects of MVA are mediated by postsqualene metabolites. Using rapid amplification of cDNA ends (RACE), we characterized the 5' end of SULT1C2 mRNA and used this information to generate constructs for promoter analysis. SQ1 and MVA increased reporter activity by ∼1.6- and 3-fold, respectively, from a construct beginning 49 base pairs (bp) upstream from the longest 5'-RACE product (-3140:-49). Sequence deletions from this construct revealed a hepatocyte nuclear factor 1 (HNF1) element (-2558), and mutation of this element reduced basal (75%) and MVA-induced (30%) reporter activity and attenuated promoter activation following overexpression of HNF1α or 1β. However, the effects of SQ1 were localized to a more proximal promoter region (-281:-49). Collectively, our findings demonstrate that cholesterol biosynthetic intermediates influence SULT1C2 expression in rat primary hepatocytes. Further, HNF1 appears to play an important role in mediating basal and MVA-induced SULT1C2 transcription.
胞质磺基转移酶1C2(SULT1C2)在大鼠的肾脏、胃和肝脏中表达;然而,调节该酶表达的机制尚不清楚。我们使用几种胆固醇合成抑制剂,评估了甲羟戊酸(MVA)衍生中间体对原代培养大鼠肝细胞中SULT1C2的转录调控。用3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂普伐他汀(30 μM)阻断甲羟戊酸的产生,使SULT1C2 mRNA含量降低约40%,而导致非甾醇类异戊二烯积累的鲨烯合酶抑制剂角鲨他汀(SQ1,0.1 μM)使mRNA含量增加了4倍。用MVA(10 mM)处理强烈诱导SULT1C2 mRNA增加12倍,抑制鲨烯环氧酶可阻断此效应,但更下游的胆固醇抑制剂则不能,这表明MVA的作用是由鲨烯后代谢产物介导的。使用cDNA末端快速扩增(RACE)技术,我们鉴定了SULT1C2 mRNA的5'末端,并利用这些信息构建用于启动子分析的构建体。SQ1和MVA分别使起始于最长5'-RACE产物上游49个碱基对(bp)(-3140:-49)的构建体的报告基因活性增加约1.6倍和3倍。该构建体的序列缺失揭示了一个肝细胞核因子1(HNF1)元件(-2558),该元件的突变降低了基础(75%)和MVA诱导(30%)的报告基因活性,并减弱了HNF1α或1β过表达后的启动子激活。然而,SQ1的作用局限于更靠近近端的启动子区域(-281:-49)。总体而言,我们的研究结果表明胆固醇生物合成中间体影响大鼠原代肝细胞中SULT1C2的表达。此外,HNF1似乎在介导基础和MVA诱导的SULT1C2转录中起重要作用。